| Interleukin (IL)-18, a biomarker of human ovarian carcinoma, is predominantly released as biologically inactive precursor. | |
| | |
MedLine Citation:
|
PMID: 21061257 Owner: NLM Status: Publisher |
Abstract/OtherAbstract:
|
Interleukin (IL)-18 is a pro-inflammatory and immune-enhancing cytokine, which exerts anti-tumor effects in vivo, mediated by the induction of interferon (IFN)γ. We previously reported that IL-18 processing is defective in epithelial ovarian carcinoma (EOC) cells, which secrete an inactive precursor (pro-IL-18) in vitro. In addition, IL-18 was reported as a potential biomarker of EOC. Here, we further investigated its role as a serological marker in human EOC and addressed its possible biological activity in vivo. Our data indicate that immunoreactive IL-18 is increased in EOC patients' sera at diagnosis as compared to age-matched healthy women. IL-18 levels were higher in the ascitic fluids than in sera, suggesting a local production in the peritoneal cavity. Indeed, immunohistochemical analysis of tumors showed IL-18 expression in cytokeratine-postive neoplastic cells, although also scattered histiocytes and some lymphoid cells stained for IL-18. The detection of human IL-18 in sera and ascitic fluids of immunodeficient mice, orthotopically implanted with human EOC cells, further suggested that circulating IL-18 is tumor-derived. However, IL-18 is not an EOC specific biomarker, as increased serum levels were found also in some endometrial cancer patients. By means of a new monoclonal antibody, we characterized IL-18 present in the ascitic fluid as pro-IL-18, which is biologically inactive. Accordingly, IFNγ was not increased in EOC patients' sera and ascitic fluids and showed no correlation with IL-18 levels. Altogether these data indicate that IL-18 in EOC fluids is predominantly tumor-derived, and that its lack of biological activity may represent a mechanism of tumor-escape. |
| | |
Authors:
|
Anna Maria Orengo; Marina Fabbi; Loredana Miglietta; Cristian Andreani; Milena Bruzzone; Andrea Puppo; Paolo Cristoforoni; Maria Grazia Centurioni; Marina Gualco; Sandra Salvi; Simona Boccardo; Mauro Truini; Tiziana Piazza; Silvana Canevari; Delia Mezzanzanica; Silvano Ferrini |
Related Documents
:
|
7464827 - Purification and characterization of cytoplasmic 14c-arginine rich basic proteins of eh... 7195067 - Tumor shedding and coagulation. 3491727 - Natural immunity against ovarian tumors. 6819977 - Antitumor and interferon-inducing activities of th69, a whole bacterial preparation of ... 1552817 - Segregation of the growth slowing effects of valproic acid from phenytoin and carbamaze... 8845487 - Relationship between doxorubicin cell sensitivity, drug-induced dna double-strand break... |
Publication Detail:
|
Type: JOURNAL ARTICLE Date: 2010-11-8 |
Journal Detail:
|
Title: International journal of cancer. Journal international du cancer Volume: - ISSN: 1097-0215 ISO Abbreviation: - Publication Date: 2010 Nov |
Date Detail:
|
Created Date: 2010-11-9 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 0042124 Medline TA: Int J Cancer Country: - |
Other Details:
|
Languages: ENG Pagination: - Citation Subset: - |
Affiliation:
|
Department of Translational Oncology, Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Body mass index and clinical response to infliximab in rheumatoid arthritis.
Next Document: Gemcitabine depletes regulatory T-cells in human and mice and enhances triggering of vaccine-specifi...